替拉扎明对多重耐药沙门菌抗菌增敏活性分析

doi:10.11843/j.issn.0366-6964.2023.10.032

摘要/Abstract

摘要： 本研究旨在探究替拉扎明对沙门菌的抗菌作用机制。通过药敏试验筛选3株多重耐药沙门菌，测定替拉扎明对多重耐药沙门菌的最小抑菌浓度（MIC）、最小杀菌浓度（MBC）、抗菌效果、时间杀菌曲线及生物被膜形成能力，并分析替拉扎明对沙门菌生长增殖、耐药表型和生物被膜形成的影响。结果表明，替拉扎明对多重耐药沙门菌有明显的抗菌作用，对沙门菌ST、ST-6和ST-7的MIC值分别为12.5、25、25 μmol·L^-1，MBC值均为50 μmol·L^-1。随着替拉扎明作用浓度的增加和作用时间的延长，在共同培养4 h后明显抑制沙门菌的生长，50 μmol·L^-1替拉扎明分别和沙门菌ST、ST-6和ST-7共培养8、20和20 h后，沙门菌被全部杀死；替拉扎明显著逆转多重耐药沙门菌的耐药表型；替拉扎明对沙门菌生物被膜的形成能力和形成量产生明显的抑制作用（P<0.000 1）。替拉扎明对多重耐药沙门菌产生明显抗菌作用，且能逆转多重耐药表型和减少生物被膜的形成。研究结果阐明了替拉扎明对多重耐药沙门菌的抗菌活性，为治疗和控制由沙门菌感染引起的疾病提供新的治疗药物。

关键词: 替拉扎明, 多重耐药沙门菌, 生物被膜, 耐药表型, 抗菌活性

Abstract: The aim of this study was to explore the antibacterial mechanism of tirapazamine (TPZ) on Salmonella. We screened three multi-drug resistant Salmonella strains through drug sensitivity test, and measured the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), antibacterial effect, time bactericidal curve and biofilm formation ability of TPZ against multi-drug resistant Salmonella. The growth and proliferation of TPZ on Salmonella, the effects of drug resistance phenotype and biofilm formation were analyzed. The results showed that TPZ had obvious antibacterial effect on multi-drug resistant Salmonella, and the MIC values respectively of Salmonella strains ST, ST-6 and ST-7 were 12.5, 25 and 25 μmol·L^-1. MBC value was 50 μmol·L^-1. With the increases of the action concentration and prolongation of the action time of TPZ, the growth of Salmonella was significantly inhibited after co-culture for 4 hours, the cultivation of 50 μmol·L^-1 of TPZ was co-cultured with Salmonella ST, ST-6 and ST-7 for 8, 20 and 20 h respectively, and all Salmonella was killed; TPZ significantly reversed the drug resistance phenotype of multi-drug resistant Salmonella; TPZ had a significant inhibitory effect on the formation ability and amount of Salmonella biofilm (P<0.0001). TPZ had obvious antibacterial effect on multi-drug resistant Salmonella, and it could reverse the multi-drug resistance phenotype and reduce the formation of biofilm. The results of the study elucidated the antibacterial activity of TPZ against multi-drug resistant Salmonella, and new therapeutic drugs had been provided for the treatment and control of infections caused by Salmonella infection.

Key words: tirapazamine, multi-drug resistant Salmonella, biofilm, resistance phenotype, antibacterial activity

中图分类号:

武周慧, 王瑜, 杜衡, 王之文, 肖爽, 武金亮, 王真. 替拉扎明对多重耐药沙门菌抗菌增敏活性分析[J]. 畜牧兽医学报, 2023, 54(10): 4362-4371.

WU Zhouhui, WANG Yu, DU Heng, WANG Zhiwen, XIAO Shuang, WU Jinliang, WANG Zhen. Analysis of the Antibacterial Sensitization Activity of Tirapazamine against Multi-Drug Resistant Salmonella[J]. Acta Veterinaria et Zootechnica Sinica, 2023, 54(10): 4362-4371.

参考文献 32

[1]	付宇, 吴晓敏, 孟庆敏, 等. 食品中沙门菌分布特征及耐药性研究[J]. 中国卫生检验杂志, 2023, 33(2):139-142, 146.FU Y, WU X M, MENG Q M, et al. Research on drug resistance and distribution characteristics of Salmonella in food[J]. Chinese Journal of Health Laboratory Technology, 2023, 33(2):139-142, 146(in Chinese)
[2]	ANSARI N, YAZDIAN-ROBATI R, SHAHDORDIZADEH M, et al. Aptasensors for quantitative detection of Salmonella Typhimurium[J]. Anal Biochem, 2017, 533:18-25.
[3]	GARAI P, GNANADHAS D P, CHAKRAVORTTY D. Salmonella enterica serovars Typhimurium and Typhi as model organisms:revealing paradigm of host-pathogen interactions[J]. Virulence, 2012, 3(4):377-388.
[4]	GAL-MOR O. Persistent infection and long-term carriage of typhoidal and nontyphoidal Salmonellae[J]. Clin Microbiol Rev, 2018, 32(1):e00088-18.
[5]	许敬平, 靳连群, 冯华, 等. 沙门菌食物中毒的研究进展[J]. 人民军医, 2018, 61(3):274-277.XU J P, JIN L Q, FENG H, et al. Research progress of Salmonella food poisoning[J]. People's Military Surgeon, 2018, 61(3):274-277. (in Chinese)
[6]	BESSER J M. Salmonella epidemiology:a whirlwind of change[J]. Food Microbiol, 2018, 71:55-59.
[7]	CHAUDHARI R, SINGH K, KODGIRE P. Biochemical and molecular mechanisms of antibiotic resistance in Salmonella spp.[J]. Res Microbiol, 2023, 174(1-2):103985.
[8]	GUAN Y, LI Y W, LI J, et al. Phenotypic and genotypic characterization of antimicrobial resistance profiles in Salmonella isolated from waterfowl in 2002-2005 and 2018-2020 in Sichuan, China[J]. Front Microbiol, 2022, 13:987613.
[9]	BUMANN D. Has nature already identified all useful antibacterial targets?[J]. Curr Opin Microbiol, 2008, 11(5):387-392.
[10]	韩雷强. 基于小分子的自组装纳米药物的设计、制备及抗肿瘤活性评价[D]. 济南:山东大学, 2018.HAN L Q. Design, preparation and evaluation of small molecular based nanodrug for cancer therapy[D]. Ji'nan:Shandong University, 2018.
[11]	MARCU L, OLVER I. Tirapazamine:from bench to clinical trials[J]. Curr Clin Pharmacol, 2006, 1(1):71-79.
[12]	SLIWINSKA J, DUDKA J, KORGA A, et al. Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca2+ balance protein levels[J]. Oxid Med Cell Longev, 2012, 2012:890826.
[13]	SHAH Z, MAHBUBA R, TURCOTTE B. The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile[J]. Fems Microbiol Lett, 2013, 347(1):61-69.
[14]	LI Q, LIU Y M, GUO X P, et al. Tirapazamine-loaded CalliSpheres microspheres enhance synergy between tirapazamine and embolization against liver cancer in an animal model[J]. Biomed Pharmacother, 2022, 151:113123.
[15]	AJNAI G, CHENG C C, KAN T C, et al. Improving tirapazamine (TPZ) to target and eradicate hypoxia tumors by gold nanoparticle carriers[J]. Pharmaceutics, 2022, 14(4):847.
[16]	中华人民共和国国家卫生和计划生育委员会, 国家食品药品监督管理总局. GB 4789. 4-2016 食品安全国家标准食品微生物学检验沙门氏菌检验[S]. 北京:中国标准出版社, 2017.National Health and Family Planning Commission of PRC, China Food and Drug Administration. GB 4789. 4-2016 Microbiological examination of foodhygiene-Examination of Salmonella[S]. Beijing:Standards Press of China, 2017(in Chinese)
[17]	SIVARANJANI M, PRAKASH M, GOWRISHANKAR S, et al. In vitro activity of alpha-mangostin in killing and eradicating Staphylococcus epidermidis RP62A biofilms[J]. Appl Microbiol Biotechnol, 2017, 101(8):3349-3359.
[18]	DRAUCH V, IBESICH C, VOGL C, et al. In-vitro testing of bacteriostatic and bactericidal efficacy of commercial disinfectants against Salmonella Infantis reveals substantial differences between products and bacterial strains[J]. Int J Food Microbiol, 2020, 328:108660.
[19]	HANEY E F, TRIMBLE M J, CHENG J T, et al. Critical assessment of methods to quantify biofilm growth and evaluate antibiofilm activity of host defence peptides[J]. Biomolecules, 2018, 8(2):29.
[20]	KROM B P, COHEN J B, MCELHANEY FESER G E, et al. Optimized candidal biofilm microtiter assay[J]. J Microbiol Methods, 2007, 68(2):421-423.
[21]	CHOUSALKAR K, GAST R, MARTELLI F, et al. Review of egg-related salmonellosis and reduction strategies in United States, Australia, United Kingdom and New Zealand[J]. Crit Rev Microbiol, 2018, 44(3):290-303.
[22]	KNODLER L A, ELFENBEIN J R. Salmonella enterica[J] Trends Microbiol, 2019, 27(11):964-965.
[23]	李宁, 白莉. 中美欧食源性细菌耐药性监测系统比较研究及启示[J]. 食品科学技术学报, 2023, 41(1):1-9, 21.LI N, BAI L. Comparative study on foodborne bacterial antimicrobial resistance surveillance system in China, America and Europe and its implication[J]. Journal of Food Science and Technology, 2023, 41(1):1-9, 21. (in Chinese)
[24]	CHEN Z Q, BAI J, WANG S J, et al. Prevalence, antimicrobial resistance, virulence genes and genetic diversity of Salmonella isolated from retail duck meat in southern China[J]. Microorganisms, 2020, 8(3):444.
[25]	ZHANG Q Q, YING G G, PAN C G, et al. Comprehensive evaluation of antibiotics emission and fate in the river basins of China:source analysis, multimedia modeling, and linkage to bacterial resistance[J]. Environ Sci Technol, 2015, 49(11):6772-6782.
[26]	KLEIN E Y, VAN BOECKEL T P, MARTINEZ E M, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015[J]. Proc Natl Acad Sci U S A, 2018, 115(15):E3463-E3470.
[27]	Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019:a systematic analysis[J]. Lancet, 2022, 399(10325):629-655.
[28]	VESTBY L K, GRØNSETH T, SIMM R, et al. Bacterial biofilm and its role in the pathogenesis of disease[J]. Antibiotics (Basel), 2020, 9(2):59.
[29]	SHARMA G, SHARMA S, SHARMA P, et al. Escherichia coli biofilm:development and therapeutic strategies[J]. J Appl Microbiol, 2016, 121(2):309-319.
[30]	LISTER J L, HORSWILL A R. Staphylococcus aureus biofilms:recent developments in biofilm dispersal[J]. Front Cell Infect Microbiol, 2014, 4:178.
[31]	VAN WOLFEREN M, ORELL A, ALBERS S V. Archaeal biofilm formation[J]. Nat Rev Microbiol, 2018, 16(11):699-713.
[32]	HALL C W, MAH T F. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria[J]. FEMS Microbiol Rev, 2017, 41(3):276-301.